Therapy of the acute coronary syndrome. ASA, heparin, LMWH, hirudin and the GP-IIb/IIIa blockers;Therapie des akuten koronarsyndroms: ASS, heparin, LMWH, hirudin und GP- IIb/IIIa-blocker

Herz

Volumn 24, Issue 5, 1999, Pages 353-362

  Gaede, Andreas ^b   Terres, Wolfram ^a  

^a ALLGEMEINES KRANKENHAUS CELLE   (Germany)

^b NONE

Author keywords

ASA; Coronary syndrome; GP IIb IIIa blockers; Heparin; Hirudin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; BLOOD CLOTTING; COMPETITIVE INHIBITION; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS; OUTCOMES RESEARCH; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

EID: 0032743183     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03043926     Document Type: Article

References (83)

1. Alexander JH, Newby LK, Moliterno DJ, et al. Relationship of outcomes to treatment with lamifiban in patients undergoing PTCA: analysis of PARAGON A. J Am Coll Cardiol 1997;29: 409A.abstract.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308: 81-106.
3. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safty report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994;90:1624-30.
4. Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;95:809-13
5. Blankenship JC. Incidence of thrombocytopenia complicating treatment with glycoprotein IIb/IIIa receptor inhibitor. J Am Coll Cardiol 1999;33:Suppl A:255A.
6. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985;313:1369-71.
7. CAPTURE. Randomised plazebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-35.
8. Carłson JA, Benthin AS, Peterson A, et al. Differential inhibition of thromboxane A2 and prostacyclin synthesis by low dose acetylsalicylic acid in atherosclerotic patients. Thromb Res 1990; 57:437-44.
9. Charman WN, Kerins DM, Fitzgerald GA. Aspirin: pharmcokinetics and pharmacodynamic effects on platelets and vascular function. In: Vane JR, Botting RM. eds. Aspirin and other salicylates. London: Chapman & Hall, 1992:74-106.
10. Cohen M, Demers C, Gurfinkel E, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
11. DeMarco L, Girolami A, Zimmermann TS, et al. Von Willebrand factor interaction with the glycoprotein IIb/IIIa complex. Its role on platelet function as demonstrated in patients with congenital afibriongenemia. J Clin Invest 1986;77:1272-7.
12. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularisation. N Engl J Med 1997;336:1689-96.
13. The EPISTENT investigators. Randomised plazebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with the use of platelet glycoproteinIIb/IIIa blockade. Lancet 1998;352:87-92.
14. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol 1989; 63:114-20.
15. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarktion and/or sudden death. Circulation 1985;71:699-708.
16. Faulds D, Sorkin EM. Abciximab (c7E3 Fab). Drugs 1994;48: 583-98.
17. Ferguson JJ, Lau TK. Newer antithrombotic and antiplatelet agents for acute coronary syndromes. Acute Coronary Syndromes 1997;1:1.
18. Ferguson JJ. Meeting highlights of the 20th Congress of the European Society of Cardiology. Circulation 1999;99:1127-31.
19. Ferguson JJ. Meeting highlights of the American Heart Association 68th Scientific Sessions, Anaheim, California, November 3-15, 1995. Circulation 1996;93:843-6.
20. Ferguson JJ. Meeting highlights of the American College of Cardiology 45th Annual Scientific Sessions, Orlando, Florida, March 24-27, 1996. Circulation 1996;94:1-5.
21. Ferguson JJ. Meeting highlights of the 46th Annual Scientific Sessions of the American College of Cardiology. Circulation 1997;96:367-71.
22. Fiore L, Deykin D. Anticoagulant therapy. In: Beutler E, Lichtman MA, Coller BS, et al., eds. Williams hematology, 5th edn. New York: McGraw-Hill, 1995:1562-84.
23. Fischer MJ, Gunn B, Harms CS, et al. Non-peptide RGD surrogates which mimic a Gly-Asp beta-turn: potent antagonist of platelet glycoprotein IIb-IIIa. J Med Chem 1997;40:2085-101.
24. Forth W, Rummel W. Antikoagulantien, Aggregationshemmer, Fibrinolytika und Hemmstoffe der Fibrinolyse. In: Forth W, Henschler D, Rummel W, et al., Hrsg. Allgemeine und spezielle Pharmakologie und Toxikologie, 6. Aufl. Mannheim-Leipzig-Wien-Zürich: BI-Wiss.-Verlag, 1992:437-56.
25. Funk C, Funk LB, Kennedy M, et al. Human platelet/erythroleukemia cell PGG/H synthase: cDNA cloning, expression, mutagenesis and gene chromosomal assignment. FASEB J 1991;5: 2304-12.
26. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-35.
27. Greinacher A, Pötsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterisation of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247-51.
28. Greinacher A, Eichler P. Die Heparin-assozierte Thrombozytopenie - Klinik, Labordiagnostik, Pathophysiologie und Therapie. DG Klinische Chemie Mitteilungen 1995;5:195-204.
29. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-8.
30. GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;94:1-5.
31. Hamm CW, Terres W, Bleifeld W. Definition und Pathogenese der instabilen Angina pectoris. Dtsch Med Wochenschr 1989; 114:507-10.
32. Hamm CW, Kupper W, Kentsch M, et al. Intracoronare Thromben bei Patienten mit instabiler Angina pectoris. Dtsch Med Wochenschr 1987;112:1812-5.
33. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of Abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1623-9.
34. Hirsh J, Dalen JE, Fuster V, et al. Aspirin and other platelet-active drugs. Chest 1995;108:247S-57S.
35. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79:1-17.
36. Hoffmeister HM, Jur M, Wendel HP, et al. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation 1995;91:2520-7.
37. Juul-Möller S, Edvardson B, Jahnmatz A, et al., for the Swedish Angina Pectoris Trial (SAPAT) Group. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;340:1421-5.
38. Kaiser B. Anticoagulant and antithrombotic action of recombinant hirudin. Semin Thromb Hemost 1991;17:130-5.
39. Kereiakes DJ, Essell JH, Abbottsmith CW, et al. Abciximab-associated profound thrombocytopenia: therapy with immunoglobin and platelet transfusion. Am J Cardiol 1996;78:1161-3.
40. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with plazebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997;96:61-8.
41. Kloczewiak M, Timmons S, Lukas TJ. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemistry 1984;23:1767-74.
42. Knapp HR, Healy C, Lawson GA, et. Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men. Thromb Res 1988, 50:377-386
43. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994;90:1522-36.
44. Lefkovits J, Topol EJ. Platet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J 1996;17:9-18.
45. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against myocardial infarction and death in men with unstable angina. N Engl J Med 1983;309:396-403.
46. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
47. Lincoff AM, Tcheng JE, Califf RM, et al. Standard versus low-dose weight-adjusted hepparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) during percutaneous coronary revascularisation. PROLOG Investigators. Am J Cardiol 1997;79:286-91.
48. Moliterno DJ, Caloff RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the prevention of ishemic complications trial. Am J Cardiol 1995;75:559-62.
49. Moreno PR, Bernadi V, López-Cuéllar J, et al. Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation 1996;94:3098-102.
50. Moreno PR, Bernadi V, López-Cuéllar J, et al. Macrophages, smooth muscle cells and tissue factor in unstable angina. Circulation 1996;94:3090-7.
51. Moreno PR, Falk E, Palacios IF, et al. Macrophage infiltration in acute coronary syndromes, implications for plaque rupture. Circulation 1994;90:775-7.
52. Nicholson NS, Panzer KS, Salyers AK. Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa inhibition by arginine-glycine-aspartic acid serine (RGDS) and arginine-glycine-aspartic acid (RGD) O-me)Y (SC-46749). J Pharmacol Exp Ther 1991;256:876-82.
53. Nurden AT, Nurden PA. A review of the role of platelet membrane glycoproteins in the platelet-vessel wall interaction. Bailiére's Clin Haemat 1993;6:653-90.
54. Ohmann EM, Kleimann NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997;95:846-54.
55. Oler A, Wholey MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with iunstable angina. A meta-analysis. JAMA 1996;276: 811-5.
56. Organisation to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation 1997;97:769-77.
57. Pedersen AK, FitzGerald GA. Dose related kinetics of aspirin. Presystemic acetylation and platelet cyclooxygenase. N Engl J Med 1984;311:1206-11.
58. Pierschbacher MD, Ruoslathi E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984;309:30-3.
59. Plow EF, D'Souza SE, Ginsberg MH. Ligand binding to GP IIb-IIIa: A status report. Semin Thromb Hemost 1992;18:324-32.
60. PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498-505
61. PRISM-PLUS Study Investigators. Inhibition of the platelet glykoprotein IIb/IIIa receptor with tirofibran in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
62. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
63. Ranke C, Creutzig A, Luska G, et al. Dosisabhängige Nebenwirkungen der Acetylsalicylsäuretherapie. Ergebnisse einer prospektiven, randomisierten klinischen Studie bei Patienten mit peripherer arterieller Verschlußkrankheit. Med Klin 1993;88:571-6.
64. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary disease. Lancet 1990;336:827-30.
65. Shattil SJ, Hoxie JA, Cunningham M, et al. Changes in the platelet membrane glycoprotein IIb /IIIa complex during platelet activation. J Biol Chem 1985;260:1107-4.
66. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981;1:1225-8.
67. Terres W. Akute und chronische Mechanismen der Arteriosklerose. In: Fritz Reinhard Matthias FR, Raschke H, Hrsg. 40. Hamburger Symposium über Blutgerinnung, Aktuelle Entwicklungen in der Behandlung mit Antikoagulanzien und Thrombozytenfunktionshemmern. Stuttgart: Schattauer, 1998.
68. Théroux P, Fuster V. Acute coronary syndromes. Unstable angina and non-Q-wave myocardial infarction. Circulation 1998;97: 1195-206.
69. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-11.
70. Théroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327: 141-5.
71. Topol EJ, Bonan J, Jewitt D, et al. Use of direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-9.
72. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta-3 blockade with percutaneus coronary intervention. EPIC Investigator Group. Evaluation of platelet IIb/IIIa inhibition for prevention of ischemic complication. JAMA 1997;2789: 479-84.
73. Rauch U, Chesebro JH, Fuster V, et al. Unstable angina and the role of thrombus. Acute Coronary Syndromes 1997;1:2-8.
74. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
75. The SCATI Group. Randomized controlled trial of subcutaneous calcium-heparin in acute myocardial infarktion. Lancet 1989;2:182-6.
76. Schafer AI. Low-molecular-weight heparin - an opportunity for home treatment of venous thrombosis. N Engl J Med 1996;334: 724-5.
77. Simoons ML. Platelet glycoprotein IIb/IIIa receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. Eur Heart J 1998;19:1608-16.
78. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-82.
79. Van de Werf F. PARAGON. 19th Congress of the European Society of Cardiology, Stockholm, Sweden, August 24-28, 1997.
80. Wallentin L, Ohlsson J, Swahn E. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347: 561-7.
81. Ware JA, Coller BS. Platelet morphology, biochemistry and function. In: Beutler E, Lichtman MA, Coller BS, et al., eds. Williams hematology, 5th edn. New York: McGraw-Hill, 1995: 1161-201.
82. Weisel JW, Nagaswami C, Vilaire G, et al. Examination of the platelet membrane glycoprotein IIb-IIIa complex and ist interaction with fibrinogen and other ligands by electron microscopy. J Biol Chem 1992;267:16637-43.
83. Weitz J. New anticoagulant strategies. Current status and future potential. Drugs 1994;48:485-97.